Your browser doesn't support javascript.
loading
Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study.
Saito, Kei; Michihata, Nobuaki; Hamada, Tsuyoshi; Jo, Taisuke; Matsui, Hiroki; Fushimi, Kiyohide; Nakai, Yousuke; Yasunaga, Hideo; Fujishiro, Mitsuhiro.
Afiliação
  • Saito K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Michihata N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Hamada T; Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Jo T; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Matsui H; Department of Hepato-Biliary-Pancreatic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Fushimi K; Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Nakai Y; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Yasunaga H; Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  • Fujishiro M; Department of Health Informatics and Policy, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Cancer Sci ; 114(10): 3996-4005, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37547944
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article